Question 1

What is Pharvaris?

Accepted Answer

Pharvaris is a Entity.

Question 2

How often does Pharvaris appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Pharvaris first tracked by Ergen?

Accepted Answer

First tracked on May 29, 2026.

Question 4

When was Pharvaris last mentioned in news?

Accepted Answer

Last active on Jul 06, 2026.

Question 5

What is Pharvaris's current news sentiment?

Accepted Answer

Aggregate sentiment score: 75 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Pharvaris in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Pharvaris?

Accepted Answer

FDA Accepts Pharvaris Deucrictibant NDA (Jul 06, 2026, 6 articles).

Question 8

How did the "FDA Accepts Pharvaris Deucrictibant NDA" event impact Pharvaris?

Accepted Answer

Pharvaris' New Drug Application for deucrictibant IR has been accepted by the United States — Food and Drug Administration for the on-demand treatment of Hereditary Angioedema attacks, marking a significant milestone for the company and its potential to launch a new therapy. This acceptance validates years of research and development, positioning Pharvaris for potential commercial success if the drug is approved.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.